OR WAIT 15 SECS
Ganeden said that this research further validate's Staimune's track record of immune health support.
Earlier this summer, Ganeden (Cleveland) launched its newest immune-health ingredient, Staimune. Now, the global probiotic supplier is announcing further research validating the novel ingredient’s track record of immune health support.
Staimune is made using inactivated cells of Ganeden’s flagship ingredient, the patented, shelf-stable probiotic strain GanedenBC30 (Bacillus coagulans GBI-30, 6086). Living B. coagulans GBI-30, 6086 has been the subject of extensive research into its immunity support, and a new study1 shows that even when inactivated, those cells continue to confer immune benefits.
In the study, published in August in the Journal of Inflammation Research, researchers treated in vitro cultures of human peripheral blood mononuclear cells (PBMCs) from healthy donors with inactivated B. coagulans GBI-30, 6086 cells for 24 hours. After incubation, the researchers monitored the PBMCs and found robust increases in the immune-activating cytokines IL-1β, IL-6, IL-17A, and TNF-α. Levels of the chemokines MCP-1, MIP-1α, and MIP-1β; the anti-inflammatory cytokines IL-1ra and IL-10; and the growth factor G-CSF-involved in repair and stem cell biology-also rose.
Thus, the study’s authors concluded, inactivated B. coagulans GBI-30, 6086 cells do trigger a response in human immune cells, altering their production of both immune-activating and anti-inflammatory cytokines and chemokines. The authors also make special note of the selective upregulation of the G-CSF growth factor, which is important in post-injury and post-inflammation repair and regeneration. The findings suggest that key immunogenic components of the bacterial cell wall remains undamaged even following inactivation and thus retain biological activities demonstrated in those of live bacteria.
This twenty-seventh study published on a Ganeden product “validates what the science team had previously discovered,” said David Keller, Ganeden’s vice president of scientific operations, in a press release. To wit, “Staimune does an exceptional job supporting immune health regardless of the inactivation process. Science is a driving factor behind all Ganeden offerings, and the extensive and ongoing research being conducted on Staimune gives manufacturers confirmation that the new ingredient will deliver the immune benefits consumers want.”
Suitable for use in functional foods and beverages, including shelf-stable beverages and high-water-activity environments that challenge live probiotics, the ingredient is FDA GRAS in products aimed at children and adults, and Ganeden has notified FDA of its self-affirmed GRAS status for infant formula.
Ganeden also recently completed a human trial the initial findings of which demonstrate Staimune’s immune support in response to a range of stressors. Details of that trial, the company says, will be released at a later date.